London, UK, 29 September 2014: MRC Technology (MRCT), a UK medical research charity, today announced the appointment of Dr. John Stageman as Chair of its Board of Directors, and who takes over from John Jeans, the charity’s Chair for the last six years.
Dr. Stageman has a wealth of experience in the pharmaceutical industry and biotechnology research. He has held a number of international R&D senior management roles at AstraZeneca, from drug discovery through to global clinical development. Latterly he led the team responsible for developing AstraZeneca’s competitive biopharmaceutical strategy, resulting in the acquisition of Cambridge Antibody Technology and of MedImmune. After a period as General Manager of MedImmune Cambridge, Dr Stageman returned to AstraZeneca as Vice President of UK Science Affairs before retiring in 2011.
Dr. Stageman was formerly Chair of the HealthTech and Medicines Knowledge Transfer Network for the Technology Strategy Board (TSB) and a Council member of the Biotechnology and Biological Sciences Research Council (BBSRC). He is Chair of the Major Awards Committee of the Biomedical Catalyst on behalf of the MRC and TSB, and is currently a lay Governor of the University of Manchester where he is also an Honorary Professor of Life Sciences. John was awarded the OBE for his services to the UK Biotechnology Industry in the 2011 New Year’s Honours list.
Dave Tapolczay, MRC Technology’s CEO, commented: “Our previous chair John Jeans has made an invaluable contribution to MRCT’s growth and success over his six year term. We thank him for his dedication and service, and wish him well in his role as the government’s life science advisor. We now welcome John Stageman and I would like to extend our thanks to him for taking up this post with MRCT. We look forward to working with him during this next stage of development of the organisation.”
John Stageman added: “I am delighted to be joining MRCT at this exciting time, as we realise our objective of progressing scientific discoveries into therapeutic treatments. Our next phase will be delivered from a new location, Stevenage Bioscience Catalyst, a move that represents a key stage in MRCT’s development and further strengthens the already thriving collaboration between academia and industry. It is a privilege to be taking the helm from John Jeans and I wish him well in his future endeavours.”
Contacts
Media enquiries
Sarah Jeffery
Zyme Communications
E-mail: sarah.jeffery@zymecommunications.com
Phone: +44 (0) 7771 730919
At MRC Technology
Suzy Hargreaves
Marketing & Communications Officer
E-mail: shargreaves@tech.mrc.ac.uk
Phone: +44 (0)20 7391 2798
About MRC Technology
MRC Technology (www.mrctechnology.org) is an independent life science medical research charity, offering professional services to organisations within the academic, charity, biotechnology and pharmaceutical sectors globally. Services include IP management and research and development for diagnostics, small molecules and therapeutic antibodies. MRC Technology bridges the gap between basic medical research and commercialisation, helping early discoveries progress to clinical application.
Please note MRC Technology has been independent from the UK’s Medical Research Council (MRC) since 2000.
Help employers find you! Check out all the jobs and post your resume.
